Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 89 Records) |
| Query Trace: Disease Progression and PIK3CA[original query] |
|---|
| Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer. British journal of cancer 2022 Sep . Fernandez-Garcia Daniel, Nteliopoulos Georgios, Hastings Robert K, Rushton Amelia, Page Karen, Allsopp Rebecca C, Ambasager Bana, Gleason Kelly, Guttery David S, Ali Simak, Charles Coombes R, Shaw Jacqueline |
| Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer. The Prostate 2022 6 82 (13): 1264-1272. Bray Alexander W, Duan Rong, Malalur Pannaga, Drusbosky Leylah M, Gourdin Theodore S, Hill Elizabeth G, Lilly Michael |
| Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA. OncoTargets and therapy 2022 5 15 571-584. Li Jie, Chen Siwen, Xue Hui, Wang Haoyi, Huang Tianwei, Xie Hongya, He Jiang, Ke Cai, Yu Zhaonan, Ni B |
| Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients. Journal of translational medicine 2022 05 20 (1): 211. Liao Hao, Zhang Jiayang, Zheng Tiantian, Liu Xiaoran, Zhong Jianxin, Shao Bin, Dong Xiaoxi, Wang Xiaohong, Du Pan, King Bonnie L, Jia Shidong, Yu Jianjun, Li Huipi |
| Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers. Targeted oncology 2022 4 17 (2): 177-185. Takeda Hiroyuki, Imoto Kiyomi, Umemoto Kumiko, Doi Ayako, Arai Hiroyuki, Horie Yoshiki, Mizukami Takuro, Oguri Tomoyo, Ogura Takashi, Izawa Naoki, Yamamoto Hiroyuki, Yamano Yoshihisa, Sunakawa |
| Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO precision oncology 2022 2 6 e2100424. Krop Ian E, Jegede Opeyemi A, Grilley-Olson Juneko E, Lauring Josh D, Mitchell Edith P, Zwiebel James A, Gray Robert J, Wang Victoria, McShane Lisa M, Rubinstein Larry V, Patton David, Williams P Mickey, Hamilton Stanley R, Kono Scott A, Ford James M, Garcia Agustin A, Sui Xingwei D, Siegel Robert D, Slomovitz Brian M, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith |
| Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. The oncologist 2022 12 . Azzi Georges, Tavallai Mehrad, Aushev Vasily N, Koyen Malashevich Allyson, Botta Gregory P, Tejani Mohamedtaki A, Hanna Diana, Krinshpun Shifra, Malhotra Meenakshi, Jurdi Adham, Aleshin Alexey, Kasi Pashtoon |
| Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer. Breast cancer research and treatment 2022 11 197 (2): 369-376. Burnette Sarah E, Poehlein Emily, Lee Hui-Jie, Force Jeremy, Westbrook Kelly, Moore Heather |
| Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. JCO precision oncology 2023 9 7 e2200694. Milena Urbini, Giorgia Marisi, Irene Azzali, Giulia Bartolini, Elisa Chiadini, Laura Capelli, Gianluca Tedaldi, Davide Angeli, Matteo Canale, Chiara Molinari, Francesca Rebuzzi, Alessandra Virga, Andrea Prochowski Iamurri, Laura Matteucci, Francesco Giulio Sullo, Silvia Angela Debonis, Chiara Gallio, Giovanni Luca Frassineti, Giovanni Martinelli, Paola Ulivi, Alessandro Passar |
| Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy. Yonsei medical journal 2023 8 64 (9): 531-540. Seung-Hyun Jung, Choong-Kun Lee, Woo Sun Kwon, Sujin Yun, Minkyu Jung, Hyo Song Kim, Hyun Cheol Chung, Yeun-Jun Chung, Sun Young R |
| Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer. Cancer genetics 2023 8 278-279 9-16. Tine Henrichsen Schnack, Douglas-V N P Oliveira, Anne Pernille Christiansen, Claus Høgdall, Estrid Høgda |
| Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer. Breast cancer research and treatment 2023 6 . Tom Wei-Wu Chen, Wen Hsiao, Ming-Shen Dai, Ching-Hung Lin, Dwan-Ying Chang, I-Chun Chen, Ming-Yang Wang, Shu-Han Chang, Shu-Min Huang, Ann-Lii Cheng, Ko-Wen Wu, Kien Thiam Tan, Yen-Shen |
| Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2?+?metastatic breast cancer. Scientific reports 2023 6 13 (1): 9928. Kyoungmin Lee, Jongwon Lee, Jungmin Choi, Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, In Hae Pa |
| Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA oncology 2023 5 . Stefania Napolitano, Vincenzo De Falco, Giulia Martini, Davide Ciardiello, Erika Martinelli, Carminia Maria Della Corte, Lucia Esposito, Vincenzo Famiglietti, Alessandra Di Liello, Antonio Avallone, Claudia Cardone, Alfonso De Stefano, Vincenzo Montesarchio, Maria Giulia Zampino, Roberto Bordonaro, Mario Scartozzi, Daniele Santini, Massimo Di Maio, Ferdinando De Vita, Lucia Altucci, Francesca Marrone, Fortunato Ciardiello, Teresa Troia |
| Genomic landscape and survival analysis of ctDNA "neo-RAS wild-type" patients with originally RAS mutant metastatic colorectal cancer. Frontiers in oncology 2023 4 13 1160673. Nicolazzo Chiara, Magri Valentina, Marino Luca, Belardinilli Francesca, Di Nicolantonio Federica, De Renzi Gianluigi, Caponnetto Salvatore, De Meo Michela, Giannini Giuseppe, Santini Daniele, Cortesi Enrico, Gazzaniga Pao |
| Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. JCO precision oncology 2023 4 7 e2200421. Wisinski Kari B, Flamand Yael, Wilson Melissa A, Luke Jason J, Tawbi Hussein A, Hong Fangxin, Mitchell Edith P, Zwiebel James A, Chen Helen, Gray Robert J, Li Shuli, McShane Lisa M, Rubinstein Lawrence V, Patton David, Williams P Mickey, Hamilton Stanley R, Behrens Robert J, Pennington Kathryn P, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith |
| Serial circulating-tumor DNA analysis with a tumor naïve next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer. Cancer research 2023 12 . Jinho Heo, Yoo-Na Kim, Saeam Shin, Kyunglim Lee, Ji-Hyun Lee, Yong Jae Lee, Zisun Choi, Jihyang Park, Seungki Min, Sang Wun Kim, Jong Rak Choi, Sunghoon Kim, Seung-Tae Lee, Jung-Yun L |
| Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer. Signal transduction and targeted therapy 2023 11 8 (1): 429. Yiqun Han, Jiayu Wang, Tao Sun, Quchang Ouyang, Jianwen Li, Jie Yuan, Binghe |
| Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer. Breast cancer research and treatment 2023 10 . Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, Takashi Takeshita, Yuichiro Kikawa, Kokoro Kobayashi, Nobutaka Iwakuma, Takuho Okamura, Hiroshi Tada, Shinji Ozaki, Toshitaka Okuno, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Sa |
| Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution. Heliyon 2023 1 8 (12): e12374. Yang Hainan, Wen Lei, Zhao Chao, Chen Jianing, Zhou Zhaoming, Zhou Cheng, Cai Linbo, Zhou Caic |
| Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 9 JCO2400110. Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, Andrés Cervantes, Valentina Gambardella, Erika Hamilton, Antoine Italiano, Kevin Kalinsky, Ian E Krop, Mafalda Oliveira, Peter Schmid, Cristina Saura, Nicholas C Turner, Andrea Varga, Sravanthi Cheeti, Stephanie Hilz, Katherine E Hutchinson, Yanling Jin, Stephanie Royer-Joo, Ubong Peters, Noopur Shankar, Jennifer L Schutzman, Dejan Jur |
| Detection of HPV DNA in Saliva of Patients with HPV-Associated Oropharyngeal Cancer Treated with Radiotherapy. Current oncology (Toronto, Ont.) 2024 8 31 (8): 4397-4405. Atsushi Motegi, Shun-Ichiro Kageyama, Yukie Kashima, Hidenari Hirata, Hidehiro Hojo, Masaki Nakamura, Takeshi Fujisawa, Tomohiro Enokida, Makoto Tahara, Kazuto Matsuura, Sadamoto Zen |
| Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer. International journal of cancer 2024 8 . Charlotte K Kindt, Carla L Alves, Sidse Ehmsen, Amalie Kragh, Thomas Reinert, Marianne Vogsen, Annette R Kodahl, Jeanette D Rønlev, Dilan Ardik, Anna L Sørensen, Kirstine Evald, Mia L Clemmensen, Johan Staaf, Henrik J Ditz |
| Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 7 . Rebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, Carlos Barrios, Joyce O'Shaughnessy, Steven J Isakoff, Shigehira Saji, Ruffo Freitas-Junior, Manuel Philco, Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew J Wongchenko, Sarah-Jayne Reilly, Nicholas Turn |
| Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis. Frontiers in oncology 2024 6 14 1408664. Marcin Kubeczko, Anna Polakiewicz-Gilowska, Katarzyna ?widerska, Aleksandra Le?niak, Marta Mianowska-Malec, Barbarba ?anoszka, Konstanty Chomik, Barbara Grandys, Natalya Lisovska, Barbara Bobek-Billewicz, Ewa Chmielik, Micha? Jarz |
| Prevalence and effect of PIK3CA H1047R somatic mutation among Indian head and neck cancer patients. Saudi journal of biological sciences 2024 6 31 (8): 104029. Arjita Ghosh, Anbalagan Moort |
| Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies. Journal of the anus, rectum and colon 2024 5 8 (2): 132-136. Kozo Kataoka, Takeshi Yamada, Manabu Shiozawa, Naoto Takase, Kazuma Ito, Kentaro Yamazaki, Jun Watanabe, Toshihiro Kudo, Takeshi Suto, Toshihiko Matsumoto, Kohei Murata, Yusuke Suwa, Shogen Boku, Hisateru Yasui, Nobuhisa Matsuhashi, Atsuyuki Maeda, Kiichi Sugimoto, Yusuke Matsumoto, Mitsuru Yokota, Johannes Fredebohm, Keita Mori, Masataka Ike |
| Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project. JCO precision oncology 2024 4 8 e2300647. Masaya Hattori, Victoria Serelli-Lee, Yoichi Naito, Takashi Yamanaka, Hiroyuki Yasojima, Rikiya Nakamura, Takao Fujisawa, Mitsuho Imai, Yoshiaki Nakamura, Hideaki Bando, Tsutomu Kawaguchi, Takayuki Yoshino, Hiroji Iwa |
| Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet. Oncology 2024 12 25 (12): e629-e638. Hope S Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruiz-Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas Turner, Nickolas Sophos, Juan Pablo Zarate, Christina Arce, Yu-Ming Shen, Stuart Turner, Hemanth Kanakamedala, Wei-Chun Hsu, Stephen Ch |
| A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors. Biomedicines 2024 10 12 (10): . Alessandra Virga, Caterina Gianni, Michela Palleschi, Davide Angeli, Filippo Merloni, Roberta Maltoni, Paola Ulivi, Giovanni Martinelli, Ugo De Giorgi, Sara Bravacci |
- Page last reviewed:Feb 1, 2024
- Content source: